About: What can we learn about SARS-CoV-2 prevalence from testing and hospital data?

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: What can we learn about SARS-CoV-2 prevalence from testing and hospital data? Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	What can we learn about SARS-CoV-2 prevalence from testing and hospital data?
Creator	Manski, Charles Simon, Kosali Wing, Coady Menachemi, Nir Blackburn, Justin Embí, Peter Freedman, Seth Kolb, Aaron Sacks, Daniel
Source	ArXiv
abstract	Measuring the prevalence of active SARS-CoV-2 infections is difficult because tests are conducted on a small and non-random segment of the population. But people admitted to the hospital for non-COVID reasons are tested at very high rates, even though they do not appear to be at elevated risk of infection. This sub-population may provide valuable evidence on prevalence in the general population. We estimate upper and lower bounds on the prevalence of the virus in the general population and the population of non-COVID hospital patients under weak assumptions on who gets tested, using Indiana data on hospital inpatient records linked to SARS-CoV-2 virological tests. The non-COVID hospital population is tested fifty times as often as the general population. By mid-June, we estimate that prevalence was between 0.01 and 4.1 percent in the general population and between 0.6 to 2.6 percent in the non-COVID hospital population. We provide and test conditions under which this non-COVID hospitalization bound is valid for the general population. The combination of clinical testing data and hospital records may contain much more information about the state of the epidemic than has been previously appreciated. The bounds we calculate for Indiana could be constructed at relatively low cost in many other states.
has issue date	2020-08-01(xsd:dateTime)
has license	arxiv
sha1sum (hex)	28f3929f5c6e8c5a43cb92c086d502031e020640
resource representing a document's title	What can we learn about SARS-CoV-2 prevalence from testing and hospital data?
resource representing a document's body	covid:28f3929f5c6e8c5a43cb92c086d502031e020640#body_text
is schema:about of	named entity 'conditions' named entity 'hospitalization' named entity 'prevalence' named entity 'prevalence' named entity 'COST' named entity 'CONSTRUCTED' named entity 'SMALL' named entity 'PROVIDE' named entity 'WEAK' named entity 'ESTIMATE' named entity 'VIRUS' named entity 'SEGMENT' named entity 'hospital records' named entity 'epidemic' named entity 'bounds' named entity 'valid' named entity 'data' named entity 'population' named entity 'cost' named entity 'infections' named entity 'infection' named entity 'SARS-CoV-2' named entity 'data' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'general population' named entity '0.01' named entity 'general population' named entity 'infection status' named entity 'SARS-CoV-2' named entity 'demographic data' named entity 'SARS-CoV-2' named entity 'gold standard' named entity 'general population' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'Indiana' named entity 'testing rate' named entity 'positive test' named entity 'influenza-like illness' named entity 'pregnancy' named entity 'virus' named entity 'SARS-CoV-2' named entity 'population grew' named entity 'vehicle accidents' named entity 'SARS-CoV-2' named entity 'Indiana' named entity 'SARS-CoV-2' named entity 'instrumental variable' named entity 'appendicitis' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'epidemic' named entity 'NPV' named entity 'influenza' named entity 'general population' named entity 'specific testing' named entity 'epidemic' named entity 'Regenstrief Institute' named entity 'Random Sample' named entity 'general population' named entity 'general population' named entity 'general population' named entity 'testing rate' named entity 'instrumental variable' named entity 'demographic profile' named entity 'general population' named entity 'mucus' named entity 'false negatives' named entity 'PPV' named entity 'labor and delivery' named entity 'general population' named entity 'epidemic' named entity 'Random Sample' named entity 'Bayes rule' named entity 'general population' named entity 'COVID-19' named entity 'Texas'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software